| H0 | null hypothesis |
|---|---|
| H1 | alternative hypothesis |
| LNH | large number hypothesis |
| TRH | tension-reducing hypothesis; thyrotropin-releasing hormone |
| MAO | 1) MonoAmine Oxidase 2) Maximal Acid Output |
| (3)H | hypothesis that |
|---|---|
| MAO | Catechol-0-methyltransferase and monoamine oxidase |
| MAOI | Monoamine oxidase inhibitor |
| MAO | Monoamine Oxidase |
| MAO | Monoamine oxidase activity |
| monoamine | <biochemistry> A molecule containing one amine group. Synonym: monamine. (05 Mar 2000) |
|---|---|
| monoamine neurotransmitters | A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. (12 Dec 1998) |
| monoamine oxidase | <enzyme> Catalysing breakdown of several biogenic amines, such as serotonin, adrenaline, noradrenaline, dopamine. (18 Nov 1997) |
| monoamine oxidase inhibitor | <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression. Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions. Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine. Acronym: MAOI (26 Mar 1998) |
| monoamine oxidase inhibitors | A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous. (12 Dec 1998) |
| adaptor hypothesis | A hypothesis, proposed by F.H.C. Crick, that an adaptor molecule must be present between the information-containing DNA and the protein being synthesised. (05 Mar 2000) |
| altered self hypothesis | The hypothesis that the T-cell receptor in MHC mediated phenomena recognises a syngeneic MHC Class I or Class II molecule after modification by a virus or certain chemicals. See: MHC restriction. (18 Nov 1997) |
| alternative hypothesis | In Neyman-Pearson testing of a hypothesis, the hypothesis or family of hypotheses about the numerical value of a parameter if and only if the null hypothesis is rejected as untenable. (05 Mar 2000) |
| autocrine hypothesis | That tumour cells containing viral oncogenes may have encoded a growth factor, normally produced by other cell types, and thereby produce the factor autonomously, leading to uncontrolled proliferation. (05 Mar 2000) |
| Avogadro's hypothesis | <physics> The hypothesis that equal volumes of two different gases at the same temperature and pressure contain the same number of molecules. (02 Jan 1998) |
| Bayesian hypothesis | An array of surmised values of a parameter to be severally explored in the light of a current set of data, with logical symmetry being preserved among all. The merits of each hypothesis entertained are based on quantity, the prior probability. The probability of the data conditional on the hypothesis is computed as the conditional probability for each; the product of the two for each hypothesis is the joint probability, and the ratio of each joint probability to the sum of all the joint probabilities is the posterior probability for that hypothesis. Unlike the Neyman-Pearson test of hypotheses, the answer is a statement about the hypothesis, not about the sample conditional on the hypothesis. No hypothesis is preferred or prevails by default. The procedure may be applied recursively any number of times, as the data becomes available. (05 Mar 2000) |
| Makeham's hypothesis | A development of Gompertz' hypothesis as to the force of mortality following some mathematical law. Makeham assumed that death was the consequence of two generally coexisting causes: 1) chance; 2) a deterioration or increased inability to withstand destruction. The first of these is constant, the second is an increasing geometrical progression. (05 Mar 2000) |
| gate-control hypothesis | A theory to explain the mechanism of pain; small fibre afferent stimuli, particularly pain, entering the substantia gelatinosa can be modulated by large fibre afferent stimuli and descending spinal pathways so that their transmission to ascending spinal pathways is blocked (gated). Synonym: gate-control hypothesis. (05 Mar 2000) |
| Gompertz' hypothesis | A theory that the force of mortality increases in geometrical progression, being based on the assumption that the average exhaustion of a person's power to avoid death is such that at the end of equal infinitely small intervals of time he loses equal proportions of the power to oppose destruction which he had at the commencement of each of these intervals. (05 Mar 2000) |
| chemiosmotic hypothesis | <biochemistry, cell biology> A theoretical mechanism (proposed by Mitchell) to explain energy transduction in the mitochondrion. As a general mechanism it is the coupling of one enzyme catalysed reaction to another using the transmembrane flow of an intermediate species. For example Cytochrome oxidase pumps protons across the mitochondrial inner membrane and ATP synthesis is driven by re entry of protons through the ATP synthesising protein complex. The alternative model is production of a chemical intermediate species, but no compound capable of coupling these reactions has ever been identified. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|